DEA Files Intent to Temporarily Schedule 7-OH and Three Synthetic Kratom Derivatives as Schedule I Controlled Substances

Why it matters

The DEA's move to temporarily schedule 7-OH and three synthetic derivatives marks the most significant federal kratom regulatory action to date, criminalizing the manufacture, sale, and possession of concentrated synthetic kratom products — while botanical kratom remains largely unaffected.

The big picture

Synthetic 7-hydroxymitragynine products have proliferated in gas stations and online marketplaces, often containing far higher concentrations of 7-OH than naturally occurring kratom. Following FDA warning letters in July 2025 and a $1 million product seizure in December 2025, HHS confirmed that synthetic 7-OH has no accepted medical use and a high potential for abuse — triggering this scheduling process. The action reflects the federal government's evolving approach: distinguishing botanical kratom from highly concentrated synthetic derivatives.

Key findings

• DEA filed two Notices of Intent with the Federal Register on July 1, 2026 to temporarily place 7-OH above a specified threshold into Schedule I of the Controlled Substances Act
• The three additional substances targeted are mitragynine pseudoindoxyl (MP), dihydro-7-hydroxymitragynine (MGM-15), and the 9-fluoro derivative of 7-hydroxymitragynine (MGM-16)
• Botanical kratom products with naturally occurring 7-OH below the specified threshold are explicitly excluded from this action
• Once temporary scheduling orders take effect, manufacture, distribution, sale, and possession of covered substances become subject to criminal, civil, and administrative CSA provisions
• DEA lab findings show commercial products often contain much higher 7-OH concentrations than naturally occurring kratom plant material

What they say

"Today's action targets highly concentrated, synthetic 7-OH products, which pose a growing threat to public safety and health. Temporarily scheduling these substances underscores the emphasis this Administration has put on the safety, health and well-being of the American people," said DEA Administrator Terrance Cole.

Bottom line

The DEA's July 1, 2026 temporary scheduling action draws a clear federal line between natural botanical kratom and synthetic, high-concentration 7-OH products — a distinction that could reshape the kratom market nationwide.